Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription 16.06.2025 1 Am J Surg Pathol 2 Br J Cancer 1 Curr Treat Options Oncol 7 Gynecol Oncol 1 Hum Pathol 4 Int J Gynecol Pathol 1 Mol Ther Oncol 1 Proc Natl Acad Sci U S A 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. MORENO-MORENO E, Caniego-Casas T, Carretero-Barrio I, Cortes A, et al
   Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors.
   Am J Surg Pathol. 2024 Sep 13. doi: 10.1097/PAS.0000000000002308.
   PubMed         Abstract available
   
   

   
   Br J Cancer

2. NARAYANAN B, Buddenkotte T, Smith H, Shah M, et al
   Growth kinetics of high-grade serous ovarian cancer: implications for early detection.
   Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03082.
   PubMed         Abstract available
   
   
3. LAGA T, Van Rompuy AS, Busschaert P, Marquina G, et al
   Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.
   Br J Cancer. 2025 Apr 23. doi: 10.1038/s41416-025-03012.
   PubMed         Abstract available
   
   

   
   Curr Treat Options Oncol

4. K RU, Elango AP, Subramanian R, Ks S, et al
   The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and Artificial Intelligence- Based Screening and Treatment.
   Curr Treat Options Oncol. 2025 Jun 9. doi: 10.1007/s11864-025-01331.
   PubMed         Abstract available
   
   

   
   Gynecol Oncol

5. XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
   Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
   Gynecol Oncol. 2025;197:34-42.
   PubMed         Abstract available
   
   
6. LOUKOVAARA M, Pasanen A, Butzow R
   Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
   Gynecol Oncol. 2025;197:96-101.
   PubMed         Abstract available
   
   
7. SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
   Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
   Gynecol Oncol. 2025;197:102-109.
   PubMed         Abstract available
   
   
8. KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
   Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
   Gynecol Oncol. 2025;197:116-120.
   PubMed         Abstract available
   
   
9. EVANS E, Dholakia J, Abraham J, Hinton A, et al
   Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
   Gynecol Oncol. 2025;197:139-145.
   PubMed         Abstract available
   
   
10. FU Z, Borho L, Taylor SE, Kelemen LE, et al
    Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
    Gynecol Oncol. 2025;198:112-129.
    PubMed         Abstract available
    
    
11. BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
    Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
    Gynecol Oncol. 2025;198:130-136.
    PubMed         Abstract available
    
    

    
    Hum Pathol

12. MILLER CH, Vemuri A, Lengyel E, Lastra RR, et al
    Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score.
    Hum Pathol. 2025;159:105800.
    PubMed         Abstract available
    
    

    
    Int J Gynecol Pathol

13. ZHAO T, Hung YP, Devins KM, Young RH, et al
    The Spectrum of Vascular Lesions of the Upper Female Genital Tract: A Report of 55 Cases.
    Int J Gynecol Pathol. 2025;44:291-307.
    PubMed         Abstract available
    
    
14. ABBASI F, Nucci MR, Doron B, Ruskin R, et al
    Case Report: ESR1::CITED2 Fusion in a Malignant Uterine Tumor Resembling Ovarian Sex Cord Tumor.
    Int J Gynecol Pathol. 2025;44:368-373.
    PubMed         Abstract available
    
    
15. NISHIJIMA Y, Inoue N, Iwase A, Ikota H, et al
    Lamin A and Emerin Protein Expression Remains Consistently Low and Nuclear Size is Unchanged in Normal Endometrium, Precancerous Lesions, and Endometrioid Carcinoma.
    Int J Gynecol Pathol. 2025;44:340-348.
    PubMed         Abstract available
    
    
16. NEMEJCOVA K, Safanda A, Kendall Bartu M, Hajkova N, et al
    HER2 Status in Low-grade Serous Ovarian Tumors.
    Int J Gynecol Pathol. 2025;44:331-335.
    PubMed         Abstract available
    
    

    
    Mol Ther Oncol

17. XING F, Wang S, Zhou J
    Retraction Notice to: The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI.
    Mol Ther Oncol. 2025;33:200991.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

18. TIEN JC, Zhai Y, Wu R, Zhang Y, et al
    Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.
    Proc Natl Acad Sci U S A. 2025;122:e2426909122.
    PubMed         Abstract available
    
    

    
    Semin Oncol

19. HSU CY, Muhammed TM, Uthirapathy S, Ahmad I, et al
    CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies.
    Semin Oncol. 2025;52:152370.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.